Pushing, Pulling Biosimilars to European Marketplace
By Sharon Kingman
Wednesday, February 20, 2013
LONDON If the European market for biosimilars could be worth $4 billion by 2017, why has progress been so slow in gaining market authorizations for biosimilars in recent years?
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.